Q3 delivered record sales, but profitability disappointed as a high share of low-margin hardware wei...
* EBIT 4% better than ABGSC and FactSet consensus * High organic growth (+27%) and record backlog (+...
Redeye comments on G5’s Q3-results which saw slightly softer revenue than expected while profitabili...
G5's results are above expectations, driven primarily by an expanded cost savings programme than the...
NoHo Partners delivered another solid quarter, demonstrating its ability to grow and improve profita...
Redeye updates on Hacksaw after Q3-results which were in line with preliminary results.
Berner Industrier delivered a strong quarter, driven by larger project deliveries for Zander & Inges...
Intervacc has reported pharmacovigilance data from the first 100,000 doses of Strangvac sold in Euro...
Redeye comments on Fable Media Group's updated full-year guidance for 2026.
Redeye comments on INQ's SEK7m raise under its existing secured convertible facility from a new US-b...
* EU member states back non-renewal of Selektope approval * Limited impact on near-term financials; ...
Redeye provides its preview ahead of Genovis’ Q3 2026 results.
Accelererande tillväxt men högre omställningskostnader Nettoomsättningen ökade med 30,3 % till 32,9...
CombinedX sells Enqore for SEK70m, 10x EBITA, well above its own market valuation.
VNV Globals större portföljbolag levererade en stark operativ utveckling, men lägre multiplar, nedsk...
Last week, EPH announced that the bulding permit for its Tegernsee project has been granted.
On Friday, NanoRepro published its H1 26 single-entity report, provided a commercial update on newke...
At its first Capital Markets Day in Frankfurt, FINEXITY presented a new organisational set-up and, f...
This morning, Moberg Pharma announced that the USPTO has granted a patent covering an improved dosin...
Redeye comments on 4C Group’s Q3 2026 report, which showed a weaker-than-expected topline as deal de...